OncoMatch/Clinical Trials/NCT05948033
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Is NCT05948033 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD70-targeting CAR-T cells for lymphoma.
Treatment: CD70-targeting CAR-T cells — In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD70 antigen expression percentage ≥ 10% (≥ 10%)
CD70 antigen expression percentage ≥ 10%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Relapse after treatment with ≥2 lines systemic therapy for all the above disease types. Relapse disease is defined as disease progression after last regimen.
Must have received: autologous stem cell transplant
Refractory post-autologous stem cell transplant (ASCT)...
Cannot have received: CD70-targeted therapy
Previously received targeting CD70 therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
anc ≥1×10^9/l; platelet count ≥50×10^9/l; hemoglobin ≥80 g/l
Kidney function
serum creatinine ≤1.5xuln
Liver function
serum ast and serum alt ≤3.0 x uln (≤5 x uln for patients with liver metastases); total serum bilirubin ≤3.0 x uln
Cardiac function
echocardiography showed left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify